FTSE 100 firm Smith & Nephew’s (LSE: SN) shares are down 21% from their 1 August 12-month high of £12.46.
Such a fall raises the possibility to me of a bargain to be had.
Why did the stock fall?
Much of the price drop followed 31 October’s Q3 results release. These saw the firm reduce its 2024 underlying revenue growth guidance to “around 4.5%” from 5%-6% previously.
And the key reason for this was the ongoing rollout of China’s Volume Based Procurement (VBP) programme. This is a scheme in which the government bulk-buys drugs through a tender mechanism aimed at securing the lowest prices.
For Smith & Nephew, this means that maintaining and then increasing profits will require higher production as prices fall. This will take time, and before then its revenues in the country will fall. The VBP effect is likely to continue into 2025, according to the firm, and remains a principal risk for it in my view.
What about the non-China business?
Otherwise, in the Q3 results, overall revenue rose 4% year on year to $1.412bn (£1.11bn). Orthopaedics revenue increased 2.3%, while Sports Medicine & Ear, Nose and Throat jumped 3.9%. Advanced Wound Management revenue was 6.5% higher.
Consensus analysts’ estimates are that Smith & Nephew’s revenue will grow by 5% a year to the end of 2026. Its earnings growth to the same point is forecast to be 22.7% each year.
Revenue is the total money a business receives, while earnings are the remainder after expenses. And it is earnings growth that ultimately drives a company’s share price and dividend over time.
Are the shares now a bargain?
On the key price-to-sales stock valuation measure, Smith & Nephew trades at just 1.9. This is bottom of its competitor group, which averages 3.
This comprises EKF Diagnostics at 2.2, Carl Zeiss Meditec at 2.3, ConvaTec at 2.8, and Sartorius at 4.8. So, it is a bargain on that basis.
The same is true on the price-to-book ratio, with Smith & Nephew presently at 2.1 against a competitor average of 3.4.
To nail down what this means in share price terms, I ran a discounted cash flow analysis. Using other analysts’ numbers and my own, this shows the stock to be 39% undervalued at its current price of £9.81.
So a fair value for the shares would be £16.08, although they may trade lower or higher than that.
What’s my verdict?
Following the Q3 results, there had been rumours of major shareholders pushing for a break-up of Smith & Nephew supposedly to unlock value.
The firm’s chairman Rupert Soames scotched these on 14 November stating that the firm’s strategy “encompasses all three of our business lines”.
If he had not done this, I would never consider buying the stock. I can do without this sort of damaging break-up talk driving the share price lower for longer.
That said, unhappy investors may continue to push for a break-up. And as it is, I am focused on high-yield stocks and Smith & Nephew returns just 3.1% a year. If it was not for this, I would seriously consider buying shares in the firm for its strong earnings growth potential. This should push the share price and dividend much higher over time, I think.
The post Down 21% and with key investors pushing for a break-up of this FTSE firm, is now the time for me to buy? appeared first on The Motley Fool UK.
Should you buy Smith & Nephew Plc now?
Don’t make any big decisions yet.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.
And he believes they could bring spectacular returns over the next decade.
Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows…
When such enormous changes hit a big industry, informed investors can potentially get rich.
So, with his new report, Mark’s aiming to put more investors in this enviable position.
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
More reading
This UK growth stock is up 100% in a year! Would I be mad to buy shares now?
2 FTSE 100 dividend shares I’ll avoid like the plague in 2025
Here’s how I’m preparing for a 2025 stock market crash
My Stocks & Shares ISA’s up more than 50% in 2024! Here’s my plan for 2025
Is Warren Buffett telling me to be fearful in 2025?
Simon Watkins has no position in any of the shares mentioned. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
